Project Manager: Boris Kovatchev, School of Medicine
The Virginia PriMeD Project: Precision Individualized Medicine for Diabetes: The purpose of this project is to detect, control (includes artificial pancreas), and cure type 1 diabetes.
BoV Approved: December 2016
Project Dates: 2/9/2017 – 2/28/2022
Funding Awarded: $16,992,531
Detection -> Control ->Cure. In the world of type 1 diabetes (T1D), these words represent a process that begins with genetic screening and early detection, employs the artificial pancreas to optimally control the disease, and aspires to a cure that will defy autoimmunity and regenerate beta cells. Interdisciplinary teams led by Drs. Stephen Rich, Boris Kovatchev and Andy Basu, and Larry Lum, respectively, are interacting through this award to create a research and clinical environment that is unique, and which positions the University as a World leader in the T1D field. The strategic goals of this project are:
- Detection: Establish a statewide network to provide genetic screening for T1D;
- Control: Create new Diabetes Data Science to unleash the power of analytics and offer: a. Optimal diabetes control based on UVA’s advanced artificial pancreas technology; b. An interdisciplinary Graduate Program to students with science/engineering background; and c. A State-of-the-art Clinical Center to bring technology to patients;
- Cure: Chart the road by investing in emerging immunotherapies and islet replacement treatments.
Current Status: Active
Three full PAC reviews and one administrative review have been conducted, each with positive final results. At the October 2020 meeting, the PAC granted a second no-cost extension so that the project team may have the opportunity to complete goals that were delayed due to COVID-19 disruptions. During the life of this award, the project team has created the administrative infrastructure necessary to pursue multiple industry collaborations and Center grants, necessary to sustain the Center beyond the life of the SIF award. They have conducted numerous pilot clinical trials to further their research. They have opened a diabetes technology clinic, translating research to the patient population. They have developed educational resources and are implementing programs with the CME office to educate UVA and other community providers on the use of diabetes technology. They have created a statewide database to identify and track children at risk of developing Type 1 Diabetes (T1D). And, finally, they are making progress with the development of novel T regulatory cells toward the treatment of T1D.